Understanding Islet Cell Transplantation

Islet cell transplantation is a targeted cellular therapy for individuals with type 1 diabetes who experience severe hypoglycemia unawareness or extreme glycemic instability despite optimal medical management. The procedure involves isolating insulin-producing islet cells from a deceased donor pancreas and infusing them into the recipient’s liver via the portal vein. Once infused, the islet cells lodge in the liver’s small blood vessels and begin sensing blood glucose levels and releasing insulin accordingly.

The Edmonton Protocol, developed in 2000 at the University of Alberta, marked a turning point in islet transplantation by demonstrating that consistent insulin independence could be achieved using a steroid-free immunosuppression regimen. Since then, refinements in donor selection, islet isolation techniques, and immunosuppressive protocols have improved outcomes. However, the procedure remains a specialized treatment reserved for patients whose diabetes is life-threatening due to recurrent severe hypoglycemia or metabolic instability. According to the Mayo Clinic, candidates typically have frequent episodes of hypoglycemia unawareness, severe metabolic instability, or have undergone a kidney transplant and need to minimize additional injury from immunosuppression.

Because the procedure requires lifelong immunosuppressive medications, it carries substantial risks. Understanding these risks alongside the realistic potential benefits forms the foundation for managing expectations before and after the transplant. This article explores the full journey—from evaluation through long-term follow-up—and provides practical guidance for setting achievable goals.

The Evolution of Islet Cell Transplantation

The concept of transplanting pancreatic tissue to treat diabetes dates back to the 1960s, but early attempts using whole pancreas or fragmented tissue faced high rates of rejection and surgical complications. The breakthrough came in 1977 when Lacy and colleagues successfully isolated islets from rodent pancreata, and human trials soon followed. The Edmonton Protocol demonstrated that a combination of low‑dose tacrolimus, sirolimus, and daclizumab could achieve insulin independence in a majority of recipients, albeit with declining durability over time.

Today, the Collaborative Islet Transplant Registry (CITR) tracks outcomes from centers worldwide. Data show continued improvement in islet isolation and patient selection, with one‑year insulin independence rates reaching 50–60% in experienced centers. However, the registry also highlights that only about 25–30% remain insulin‑free at five years, emphasizing that the procedure is not a permanent cure but a powerful tool for reducing hypoglycemia risk and improving glycemic control.

Before the Transplant: Setting the Stage

Eligibility and Evaluation Process

Not everyone with type 1 diabetes qualifies for an islet cell transplant. The evaluation is rigorous and involves a multidisciplinary team including endocrinology, transplant surgery, psychology, social work, and clinical nutrition. Eligibility criteria generally include:

  • Episodes of severe hypoglycemia (requiring assistance) despite optimal diabetes management
  • Hypoglycemia unawareness (inability to sense low blood sugar)
  • Frequent diabetic ketoacidosis (DKA) or extreme glycemic variability
  • Absence of severe obesity or other contraindications for immunosuppression
  • Good overall health with stable kidney function (since immunosuppressive drugs can harm kidneys)

During the evaluation, you will undergo extensive blood tests, cardiac stress testing, and imaging of the liver. Psychological assessments ensure you understand the lifelong commitment to medications and follow‑up. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) notes that success depends heavily on careful patient selection. Realistic expectation: The evaluation may take several months, and many people are not accepted due to medical or psychological contraindications. If you are not a candidate, other options like advanced insulin pumps or closed‑loop systems can be discussed.

The Role of Immunosuppression

Immunosuppressive drugs are necessary to prevent your immune system from attacking the donated islet cells. These medications are typically taken for life. The most common regimen includes tacrolimus and mycophenolate mofetil, sometimes with a short course of steroids (e.g., antithymocyte globulin or basiliximab) during induction. These drugs have significant side effects:

  • Increased risk of infections (bacterial, viral, fungal)
  • Kidney toxicity (nephrotoxicity)
  • Increased risk of certain cancers (especially skin cancer and lymphoma)
  • Gastrointestinal issues, tremor, high blood pressure, and high cholesterol
  • Steroids can worsen blood sugar control temporarily

Before the transplant, discuss with your transplant team how these medications will affect your daily life. Expect that you will need to take medications on a strict schedule, have regular blood draws to monitor drug levels, and avoid live vaccines. The need for lifelong immunosuppression is a major reason why islet cell transplantation is not offered to patients who can manage their diabetes with standard treatments. Understanding this trade‑off is essential for setting realistic expectations.

Realistic Expectations for Blood Sugar Control

An islet cell transplant is not a cure for type 1 diabetes. The primary goal is to eliminate severe hypoglycemia and improve blood glucose stability. Many patients become insulin‑independent for a period, but this is often temporary. According to CITR data, about 50–60% of recipients achieve insulin independence at one year, but this declines to about 25–30% at five years. However, even those who return to insulin often use significantly lower doses and experience far fewer dangerous lows. Set a goal of freedom from severe hypoglycemia rather than freedom from insulin. If your transplant eliminates episodes of hypoglycemia unawareness and allows you to maintain HbA1c in target range with minimal effort, it is considered a success.

Additional markers of success include improved glycemic variability, reduced fear of hypoglycemia, and enhanced quality of life. Discuss with your care team what outcomes are realistically possible given your specific immune profile, donor quality, and prior sensitization from previous transplants or blood transfusions.

Psychological Preparation

The emotional journey of an islet cell transplant begins long before the procedure. Patients often feel a mix of hope and anxiety. Preparing mentally involves:

  • Understanding that success is not guaranteed, and the transplant may need to be repeated (up to two or three infusions are common)
  • Accepting the possibility of side effects and complications, including graft loss
  • Building a support network of family, friends, and peer support groups
  • Working with a psychologist or psychiatrist to manage pre‑transplant anxiety and address any history of depression or anxiety disorders

Consider joining a support group for transplant recipients through organizations like the JDRF or the Diabetes Research Institute. Hearing firsthand experiences from others can help ground your expectations and prepare you for the emotional highs and lows of the process.

Financial and Logistical Considerations

Islet cell transplants are performed at specialized centers in the United States, Canada, Europe, and Australia. In the U.S., the procedure is not yet FDA‑approved and is considered experimental, though it is often covered by insurance under clinical protocols or research studies. You may face travel costs, time away from work, and lodging for the evaluation, transplant, and follow‑up visits. Expect that you will need to visit the transplant center frequently in the first year — sometimes weekly for blood work, drug level monitoring, and clinic appointments. Discuss insurance coverage, financial assistance programs, and your ability to take medical leave. Having a clear plan reduces stress later.

The Transplant Procedure: What Happens

The transplant itself is minimally invasive. Under local anesthesia or light sedation, a catheter is inserted into a vein in your abdomen (usually the portal vein) via a small incision near the belly button. The islet cells are infused over 30–60 minutes. You are usually awake during the procedure. Afterward, you stay in the hospital for 2–7 days for monitoring of blood sugar, liver function, and signs of rejection or bleeding. Expect some discomfort at the catheter site, possible nausea, and a temporary increase in blood sugar due to steroids given to prevent rejection. The islet cells need time to engraft and start functioning. It can take weeks to months to see the full benefit. Some patients note a gradual reduction in insulin needs starting around day 10–14.

After the Transplant: Navigating Recovery

Immediate Post‑Transplant Period

The first few months after transplant are the most critical. You will be on high doses of immunosuppression, which increases infection risk. You must avoid raw or undercooked foods, practice strict hand hygiene, and stay away from crowds or sick contacts. Your blood sugar may be erratic initially due to steroids, the stress of surgery, and the time needed for islet cells to establish blood flow. You will be asked to monitor blood glucose frequently (at least 4–6 times daily) and may still need to inject insulin. The transplant team will adjust your insulin doses downward as the islet cells begin producing insulin. Do not expect immediate insulin independence; improvement is often gradual.

Long‑Term Outcomes and Realistic Goals

Long‑term success varies. As mentioned, insulin independence rates decline over time. However, the primary outcome — freedom from severe hypoglycemia — is more durable. Most recipients maintain a significant and lasting improvement in hypoglycemia awareness, even if they eventually need low‑dose insulin. Other markers of success include:

  • Improved HbA1c (often below 7.0%)
  • Reduced glycemic variability
  • Improved quality of life scores
  • Decreased fear of hypoglycemia

Realistic expectation: Your transplant may need to be repeated (a second infusion from another donor) to achieve adequate islet mass. Many centers plan for two sequential transplants within the first year. After the second transplant, insulin independence rates improve. Some patients require a third infusion. Discuss the center’s typical approach to repeat transplants during your evaluation.

Managing Immunosuppressive Therapy

You will take immunosuppressants every day for the rest of your life (unless you lose graft function and the cells are rejected). These medications require vigilance:

  • Regular blood tests to monitor drug levels (tacrolimus, mycophenolate) and adjust dosing
  • Prophylactic medications to prevent infections (valganciclovir for CMV, sulfamethoxazole/trimethoprim for PCP pneumonia)
  • Monitoring kidney function, blood pressure, and cholesterol
  • Skin cancer screening annually, and possibly more often for high‑risk individuals

Side effects like tremors, diarrhea, high blood pressure, and elevated creatinine are common. Work with your transplant pharmacist and coordinator to manage these. Do not stop medications without talking to your team; rejection can occur suddenly. Also be aware that drug levels can be affected by other medications, herbal supplements, and even certain foods (e.g., St. John’s wort can lower tacrolimus levels).

Lifestyle Adjustments

Life after an islet cell transplant requires permanent lifestyle changes. You must avoid:

  • Raw or undercooked meat, fish, eggs, and unpasteurized dairy (listeria risk)
  • Grapefruit and pomegranate (can affect tacrolimus levels)
  • Contact sports or activities with high risk of liver trauma (since islet cells reside in the liver)
  • Live vaccines (MMR, varicella, yellow fever, live attenuated influenza)

You should adopt a heart‑healthy, low‑sodium diet to protect your kidneys and heart. Exercise is encouraged but avoid heavy lifting until cleared by your surgeon. Sun protection is essential due to increased skin cancer risk — use broad‑spectrum SPF 30+ sunscreen daily, wear protective clothing, and perform regular self‑skin exams.

Monitoring and Follow‑Up

Long‑term follow‑up is intensive. You will have:

  • Quarterly visits in the first year (HbA1c, C‑peptide, mixed meal tolerance test, kidney function, drug levels)
  • Annual visits indefinitely
  • Continuous glucose monitoring (CGM) to track glycemic control and detect graft dysfunction early

If you notice your blood sugars rising unexpectedly, contact your transplant team. It could signal partial graft loss and may require adjustment of immunosuppression or a boost infusion of more islet cells. CGM data can help detect subtle changes in glycemic patterns that precede a significant decline. Many recipients find that using a CGM with remote monitoring (e.g., Dexcom G6 or Abbott Libre) gives them added security.

Psychological and Emotional Management

One of the hardest parts of the transplant journey is managing emotions. Many patients experience a psychological letdown if they don’t achieve full insulin independence. You may feel disappointed, frustrated, or even guilty for being alive when your donor died. These feelings are normal. Expect emotional ups and downs. It can be helpful to keep a journal to track both blood sugar and mood. Celebrate small victories — a day without hypoglycemia, a lower insulin dose, an improved HbA1c. Talk openly with your transplant social worker or a therapist who specializes in chronic illness.

Peer support is invaluable. The Endocrine Society patient community and Facebook groups for islet cell transplant recipients allow you to share experiences and get advice from those further along the journey. Some centers also offer periodic support groups or mentor programs that pair new recipients with experienced ones.

Tips for Managing Expectations (Practical Advice)

  1. Educate yourself thoroughly from reliable sources (Mayo Clinic, NIDDK, CITR) and your transplant center’s patient education materials. Avoid using anecdotal outcomes from online forums as a benchmark.
  2. Write down your most important goals before transplant. Rank them: eliminating severe lows? Reducing insulin? Improving quality of life? After transplant, revisit these goals and adjust them as your situation evolves.
  3. Communicate openly with your care team about your concerns, side effects, and disappointments. They can offer reassurance and adjust strategies.
  4. Prepare for setbacks. You may develop infections, need to return to insulin temporarily, or face complications like bleeding or portal vein thrombosis. Knowing these risks beforehand reduces shock.
  5. Focus on the big picture: the transplant is a tool to gain stability, not a magic cure. Many recipients describe a transformative improvement in their daily lives, even if they still need basal insulin.
  6. Build a support system that includes family, friends, and healthcare professionals. Don’t isolate yourself.
  7. Maintain a healthy lifestyle to optimize graft survival and minimize side effects. Avoid smoking, limit alcohol, manage stress, and prioritize sleep.

Comparing Islet Cell Transplant with Whole Pancreas Transplant

Some patients may also be candidates for a whole pancreas transplant, often performed simultaneously with a kidney transplant. Whole pancreas transplant offers higher rates of insulin independence at five years (around 70–80%) but involves major surgery with greater risks of complications such as pancreatitis, blood clots, and graft thrombosis. Islet cell transplant is less invasive, has a shorter recovery time, and can be repeated, but has lower long‑term insulin independence rates. Discuss both options with your center to determine which aligns with your health status and goals.

The Donor Perspective

Understanding the donor side can help you appreciate the gift you receive. Islet cells come from deceased organ donors whose families consent to research or organ donation. Only a small percentage of donated pancreata are suitable for islet isolation due to factors like donor age, cause of death, and pancreas quality. Recipients are encouraged to write a letter of thanks (anonymous) to the donor family through the transplant center, which can be a meaningful part of the emotional healing process.

Conclusion

Managing expectations before and after an islet cell transplant requires honest, realistic conversations with your transplant team and yourself. The procedure offers a chance for profound improvement in diabetes control and quality of life, but it is not without significant risks and limitations. By understanding the process, the potential outcomes, and the lifelong commitment to medications and follow‑up, you can approach the journey with clarity and resilience. Celebrate every step forward, and remember that even partial success can be life‑changing. With thorough preparation and a supportive care team, many recipients find that an islet cell transplant restores a level of freedom they had not experienced since their diabetes diagnosis.